HANGZHOU, China, Dec. 13 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) , one of mainland China's leading pharmaceutical companies, today announced upcoming plans to reach out to news media, and the scientific and financial communities in North America beginning in the first quarter of 2007. "As I stated in my update to our shareholders last week, it is Aida's intention to increase transparency and continue to educate the public on what Aida has accomplished, in addition to our goals and development plans for the future," stated Mr. Jin Biao, Chairman of Aida Pharmaceuticals. "2006 was a great year of achievement for Aida, and we strongly believe that Aida will perform at or above that level in 2007. We look forward to the opportunity to meet and educate prospective institutional and retail investors in North America to convey our emerging growth story, with the goal of diversifying our float and garnering greater sponsorship." As previously announced, Aida Pharmaceutical's is planning to kick-off a year-long, multi-city North American media and investor communications tour in the first quarter 2007. The Company's executive team, including Chairman Jin Biao, intends to visit Los Angeles, Boston and New York City to further educate the public, media and investment community about the Company's established products, ongoing research and development plans and the attainment of previously disclosed growth objectives. The Company intends to meet with prospective institutional investors in addition to researching business development opportunities in North America. In each city, the Company will host a luncheon for interested investors and members of the public and media. Please contact Bethany Tomich at 617-723-1465 or for additional information. Aida Pharmaceuticals is currently developing an interactive executive presentation. This web based service will provide a complete presentation on all aspects of the Company, including its operations, product lines, research and development capabilities, financial overview, future objectives, growth prospects, etc. The presentation will be available for download and viewing by the end of the first quarter 2007, via the Company's Investor Relations website, http://www.equityperformancegroup.com/clients_aida.php. The Company has updated its Investor Profile. Interested parties can learn about the Aida management team, their corporate vision, development plans and the Company's planned pipeline of genetic and drug therapies currently being researched and developed, by visiting: http://www.equityperformancegroup.com/aida_investor_fact_sheets.php. Aida intends to make all trial information for Rh-Apo2L, in addition to other company updates, available via the Company's English website: http://www.aidapharma.com/. Investors and financial media contacts can view and download investor relations materials at http://www.equityperformancegroup.com/clients_aida.php. About Aida Pharmaceuticals: Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China: Etimicin Sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China. Contact Information: Company: Aida Pharmaceuticals, Inc. 31 Dingjiang Road Jianggan District Hangzhou, China 310016 http://www.aidapharma.com/ Investor Relations: Equity Performance Group Bethany Tomich (617) 723-1465 http://www.equityperformancegroup.com/ Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, clinical trial results, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov/. DATASOURCE: Aida Pharmaceuticals, Inc. CONTACT: Investor Relations: Bethany Tomich of Equity Performance Group, for Aida Pharmaceuticals, Inc., +1-617-723-1465, Web site: http://www.equityperformancegroup.com/clients_aida.php

Copyright